The $450 decision.

In 2019, Novo Nordisk got a bill for $450 Canadian. About $331 US. It never paid.

The patent on semaglutide in Canada lapsed the next year. With it went two years of protection in the company’s second-largest market for the molecule that became Ozempic and Wegovy.

Novo says this was not a mistake. Hold that thought.

The paper trail

The documents read like a receipt, so here they are as one.

Novo filed Canadian patent CA 2,601,784 on the semaglutide compound and paid the annual maintenance fee through 2018. Then the enthusiasm cooled. Its lawyers requested a refund of the 2017 fee, $250, because Novo wanted more time to decide whether the patent was worth keeping.

In 2019 the fee went unpaid. With the late charge, the total owed came to $450. The patent office’s letter gave Novo a one-year grace period and included a sentence that reads differently now than it did then: “Once a patent has lapsed it cannot be revived.”

Novo never paid. The patent lapsed in 2020.

the receipt

item	amount	status
Annual maintenance fee, 2017	$250 CAD	refund requested
Fee plus late charge, 2019	$450 CAD	never paid
Exclusivity, 2026 to 2028	~$2.5B per year	surrendered

What it actually cost

Here is the part almost everyone reporting this story gets wrong. The $450 did not cause Canada’s generic era. Novo’s data exclusivity expired on January 4, 2026, on its own schedule, and the patent itself would have run out in 2026 regardless.

What the $450 killed was the extension. A Certificate of Supplementary Protection linked to that patent would have carried exclusivity to 2028. Two more years.

$2.5B

Two years, at roughly $2.5 billion a year, against a $450 invoice. You have paid larger bills without reading them.

And the generic era the lapse opened early is not hypothetical. Exclusivity expired in January. Health Canada approved the first generic on April 28, the second on May 1, and Sevmia, the first generic Wegovy, on June 29. Generic semaglutide sells for $88 to $99 a month at Costco today. Sevmia’s price is still unpublished. The full dated record lives on our timeline.

Deliberate or blunder

Novo’s public position is that the non-payment was deliberate. Not an oversight, not a mailroom failure. A decision.

Walk the first reading. In 2019, semaglutide was a diabetes drug with promise, not the biggest franchise in pharmaceutical history. Companies prune patent maintenance in smaller markets all the time; it is routine portfolio hygiene. On that reading, Novo made a rational pre-blockbuster cost call that aged catastrophically, and “deliberate” is true in the least flattering way possible.

Now the second. The refund request on a $250 fee is not what strategy looks like. It is what indecision looks like. Sandoz’s CEO, asked about Canada before the paper trail surfaced, said Novo “never filed a patent in Canada. Never know why. I’m sure someone’s lost their job.” He was wrong about the filing and possibly right about everything else. On that reading, this is a paperwork failure wearing a strategy costume.

Pick whichever story you like. If it was a blunder, the best-selling drug in Canada slipped through a mail slot. If it was strategy, Novo looked at semaglutide in 2019 and decided its future was not worth $450. The receipt reads the same either way: nobody in the building thought this molecule was about to become the industry.

Here is the lesson, and it is not about paperwork. Every decision priced before 2020 got repriced by this boom. The markets ranked minor became the battlegrounds. The fees not worth paying became the most expensive bills in pharma. Canada was an afterthought on an invoice. Now it is the preview of everyone’s future, and this brief reports from it twice a week.

Watching for

• Sevmia’s price and stocking. The estimate is late July to August; the number publishes the moment it exists.
• The Plosbrio and Poviztra launch decision. Novo’s own lower-priced twins of Ozempic and Wegovy, approved December 22, 2025, still sitting unfired.
• Novo H1 results, August 5, before the market opens.

That is the brief. Same time Friday.